Accessibility Tools

GeoVax is enrolling patients in two Phase 2 vaccine studies for COVID-19 (one among immunocompromised patients and the other among
healthy volunteers), and for a Phase 2 therapy study for Advanced Head & Neck Cancer patients. Please visit Pipeline for more information.

Innovations in Immunology

GeoVax is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. 


Our lead program in oncology is Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. Our lead infectious disease program is CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations, currently in two Phase 2 clinical trials.
Register to receive email alerts for GeoVax press releases
Copyright © GeoVax 2023. All Rights Reserved.